Cited by 90Autism Spectrum Disorder ResearchAttention Deficit Hyperactivity DisorderBehavioral and Psychological Studies

A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: An analysis of secondary outcome measures

Open access
Politte, Laura C., Scahill, Lawrence, Figueroa, Janet, McCracken, James T., King, Bryan, McDougle, Christopher J.·2018·Neuropsychopharmacology

Abstract

In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms. Here, we examine the impact of GEXR on oppositional behavior, anxiety, repetitive behavior, and sleep disturbance. Sixty-two subjects with ASD (53 boys, 9 girls; ages 5-14 years) were randomly assigned to GEXR (n = 30) or placebo (n = 32) for 8 weeks. Outcomes include the Home Situation Questionnaire-Modified for ASD (HSQ-ASD), Anxiety scale of the Child and Adolescent Symptom Inventory (CASI), Children's Yale-Brown Obsessive-Compulsive Scale-Modified for ASD (CYBOCS-ASD), and Children's Sleep Habits Questionnaire (CSHQ). A repeated measures linear mixed model was used to determine the effects of treatment group and time on HSQ scores. For other measures, change from baseline was evaluated with Analysis of Covariance (ANCOVA).After 8 weeks of treatment, parent ratings of oppositional behavior on the HSQ declined by 44% (per item mean from 3.4 to 1.9) in the GEXR group compared to 12% (from 3.3 to 2.9) for placebo (p = 0.004). Repetitive behavior on the CYBOCS-ASD showed a significantly greater decline in GEXR-treated participants compared to placebo (24% vs. <1%, p = 0.01). No group differences were observed on CASI Anxiety or CSHQ (p = 0.64 and 0.75, respectively). GEXR was effective in reducing oppositional behavior and, more modestly, repetitive behavior. GEXR was not superior to placebo for anxiety, though baseline anxiety ratings were low. GEXR did not significantly improve sleep habits. Future studies could focus on repetitive behavior or anxiety, symptoms with limited treatment options.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-018-0039-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A placebo-controlled study showed guanfacine could be helpful for reducing oppositional and repetitive behaviors in autism.

    “A placebo-controlled study showed that guanfacine could be helpful for reducing oppositional and repetitive behaviors”
  • In autism, social behaviors are usually not improved by guanfacine.

    “although social behaviors are usually not improved (Politte et al., 2018)”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Politte et al., 2018

    The Introduction identifies impaired social communication as a core feature of autism, but does not say whether guanfacine improves it. The Results and Discussion report improvements in oppositional and repetitive behavior; the socialization and social-communication scores shown in Table 1 are baseline characteristics, not treatment outcomes. Our copy therefore does not establish that social behaviors are usually unimproved. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Politte, L. C., Scahill, L., Figueroa, J., McCracken, J. T., King, B., & McDougle, C. J.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Emory University (US)
  • University of California, Los Angeles (US)
  • University of California, San Francisco (US)
  • Harvard University (US)
Corresponding author
Politte, Laura C.
Venue
Neuropsychopharmacology
Published
2018-02-27
Volume
43
Issue
8
Pages
1772-1778
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2792963494
Cited by
90
References
42
Citations by year
2026: 7 · 2025: 14 · 2024: 13 · 2023: 11 · 2022: 16 · 2021: 7 · 2020: 14 · 2019: 4 · 2018: 3
FWCI
4.17
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR001111, UL1TR000454, UL1TR002378)
  • National Institute of Mental Health (R01MH086927, R01MH083707, R01MH083739, R01MH083747)
  • National Center for Research Resources (UL1RR024139)
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD087101, P50HD055784)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
autism spectrum disorder, ADHD symptoms, oppositional behavior, repetitive behavior, anxiety, sleep disorders, children, alpha-2 adrenergic agonists, Children's Sleep Habits Questionnaire
MeSH terms
Problem Behavior, Autism Spectrum Disorder, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Child, Preschool, Delayed-Action Preparations, Female, Humans, Male, Psychotropic Drugs, Sleep, Stereotyped Behavior, Guanfacine, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review